NuCana BioMed

United Kingdom
Edinburgh, Scotland, United Kingdom, EH12 9RG

Company profile

NuCana BioMed company profile

NuCana BioMed is an emerging biopharmaceutical company dedicated to the discovery, development and commercialisation of innovative, rationally designed medicines that address significant unmet medical needs. Our management team has extensive experience of building successful biopharmaceutical companies. This includes the formation and subsequent growth of Bioenvision into a NASDAQ National listed, global biopharmaceutical company, which was acquired by Genzyme Corporation in October 2007. Specific management expertise includes the development, approval and commercialisation of oncology medicines. We are developing a portfolio of first-in-class and best-in-class pharmaceutical products designed to treat life-threatening or debilitating diseases. Our primary focus is in the area of oncology, although our technology platform has broader clinical potential.

Business identity

Contact email
[email protected]
Phone number
44 13 1248 3660
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
1997-01-01, Year

Headquarters

Postal code
EH12 9RG
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
6
Total equity funding
$280.2M
Last funding
Post IPO Equity / $25.6M / 2025-07-21
Last equity funding
Post IPO Equity / $25.6M
Investors
6
Lead investors
3
Founders
1
Articles
18
Exited on
2017-09-27

Founders and investors

Founders

Hugh Griffith

Lead investors

AbingworthSofinnova InvestmentsSofinnova Partners

Investors

AbingworthMorningsideScottish EnterpriseSofinnova InvestmentsSofinnova Partners